Greenhouse gas emissions and energy balance of biodiesel production from microalgae cultivated in photobioreactors in Denmark: a life-cycle modeling

The current use of fossil fuels is problematic for both environmental and economic reasons and biofuels are regarded as a potential solution to current energy issues. This study analyzes the energy balances and greenhouse gas emissions of 24 different technology scenarios for the production of algal biodiesel from Nannochloropsis cultivated at industrial scale in photobioreactors in Denmark. Both consolidated and pioneering technologies are analyzed focusing on strengths and weaknesses which influence the performance. Based on literature data, energy balance and greenhouse gas emissions are determined in a comparative 'well-to-tank' Life Cycle Assessment against fossil diesel. Use of by-products from biodiesel production such as glycerol obtained from transesterification and anaerobic digestion of residual biomass are included. Different technologies and methods are considered in cultivation stage (freshwater vs. wastewater; synthetic CO2 vs. waste CO2), harvesting stage (flocculation vs. centrifugation) and oil extraction stage (hexane extraction vs. supercritical CO2 extraction). The choices affecting environmental performance of the scenarios are evaluated. Results show that algal biodiesel produced through current conventional technologies has higher energy demand and greenhouse gas emissions than fossil diesel. However, greenhouse gas emissions of algal biodiesel can be significantly reduced through the use of 'waste' flows (nutrients and CO2) but there are still technical difficulties with both microalgae cultivation in wastewater as well as transportation and injection of waste CO2. In any way, a positive energy balance is still far from being achieved. Considerable improvements must be made to develop an environmentally beneficial microalgae biodiesel production on an industrial scale. In particular, different aspects of cultivation need to be enhanced, such as the use of wastewater and CO2-rich flue gas from industrial power plants

In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood

Abstract Objectives The aim of this study was to report on in vitro tests of antibacterial activity of ceftazidime/avibactam in combination against planktonic or biofilm KPC carbapenemase-producing Klebsiella pneumoniae (KPC-Kp), the rate of KPC-Kp blood isolates in University of Perugia Hospital over a 5-year period, and their antimicrobial susceptibility patterns. Methods The antibacterial activity of ceftazidime/avibactam in combination with other antimicrobials was assessed against planktonic and biofilm bacteria by Etest and checkerboard assay. A retrospective review of laboratory data was performed to evaluate the rate of KPC-Kp from blood samples and their antimicrobial susceptibility patterns. Results Between 2014 and 2019, 130/4241 (3.1%) KPC-Kp were identified from blood cultures. Their rate increased from 2.3% in 2014–2015 to 4.5% over the last 3 years. Overall, 4.6% (6/130) of KPC-Kp isolates were susceptible to meropenem, 65.4% (85/130) to colistin, 65.1% (84/129) to tigecycline, 34.6% (45/130) to amikacin, 36.2% (42/116) to gentamicin, 40.2% (39/97) to fosfomycin and 91.5% (65/71) to ceftazidime/avibactam. Five of six ceftazidime/avibactam-resistant KPC-Kp were isolated from patients not treated with ceftazidime/avibactam. Synergism was detected both by Etest and checkerboard assay for the combination of ceftazidime/avibactam plus meropenem against planktonic isolates, whilst lower bactericidal activity was observed in biofilm KPC-Kp isolates. Conclusions Our in vitro data suggest that the combination of ceftazidime/avibactam plus meropenem has a synergistic antibacterial activity against planktonic bacteria, whilst a lower activity was detected against biofilm, suggesting worse clinical outcomes whenever biofilm infections are present. Further analyses are required to confirm these results before extending them to clinical practice

Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of 2 Cases.

Bisphosphonates, a group of inorganic pyrophosphate analogues that prevent the loss of bone density, are commonly used in patients with bone metastases; the calcium-mimetic a-emitter radium-223 dichloride (Ra223) is a bone-targeting therapy used in patients with metastatic castration-resistant prostate cancer (mCRPC)-related bone metastases. Both treatments reduce pain and disability; Ra223 is associated with significantly improved overall survival in mCRPC. Patients who receive bisphosphonate therapy are at risk of developing osteonecrosis of the jaw, especially in those who do not undergo an accurate oral evaluation and sanitation before the beginning of therapy, and in patients who present with conditions that facilitate the development of this problem, such as inadequate oral and dental care, lack of prophylactic antimicrobial mouth rinsing, patient comorbidity, or suboptimal suturing after tooth extraction. Although there is possible synergism between bisphosphonates and Ra223 therapy, there is no consensus about the use of Ra223 in patients with previous/current osteonecrosis of the jaw induced by zoledronic acid. However, our experience suggests that Ra223 therapy might not be contraindicated in patients with osteonecrosis of the jaw induced by zoledronic acid if an appropriate multidisciplinary approach is followed, and we report 2 cases of patients with current or previous osteonecrosis of the jaw induced by zoledronic acid, who were treated with Ra223 for mCRPCrelated bone metastases. Multidisciplinary management, including accurate clinical and radiological evaluation before beginning therapy with Ra223, together with oral sanitation and periodic controls during treatment, allowed successful administration of Ra223 while reducing side effects, with absent or minimal worsening of osteonecrosis

Inflammation: an important parameter in the search of prostate cancer biomarkers

Background A more specific and early diagnostics for prostate cancer (PCa) is highly desirable. In this study, being inflammation the focus of our effort, serum protein profiles were analyzed in order to investigate if this parameter could interfere with the search of discriminating proteins between PCa and benign prostatic hyperplasia (BPH). Methods Patients with clinical suspect of PCa and candidates for trans-rectal ultrasound guided prostate biopsy (TRUS) were enrolled. Histological specimens were examined in order to grade and classify the tumor, identify BPH and detect inflammation. Surface Enhanced Laser Desorption/Ionization-Time of Flight-Mass Spectrometry (SELDI-ToF-MS) and two-dimensional gel electrophoresis (2-DE) coupled with Liquid Chromatography-MS/MS (LC-MS/MS) were used to analyze immuno-depleted serum samples from patients with PCa and BPH. Results The comparison between PCa (with and without inflammation) and BPH (with and without inflammation) serum samples by SELDI-ToF-MS analysis did not show differences in protein expression, while changes were only observed when the concomitant presence of inflammation was taken into consideration. In fact, when samples with histological sign of inflammation were excluded, 20 significantly different protein peaks were detected. Subsequent comparisons (PCa with inflammation vs PCa without inflammation, and BPH with inflammation vs BPH without inflammation) showed that 16 proteins appeared to be modified in the presence of inflammation, while 4 protein peaks were not modified. With 2-DE analysis, comparing PCa without inflammation vs PCa with inflammation, and BPH without inflammation vs the same condition in the presence of inflammation, were identified 29 and 25 differentially expressed protein spots, respectively. Excluding samples with inflammation the comparison between PCa vs BPH showed 9 unique PCa proteins, 4 of which overlapped with those previously identified in the presence of inflammation, while other 2 were new proteins, not identified in our previous comparisons. Conclusions The present study indicates that inflammation might be a confounding parameter during the proteomic research of candidate biomarkers of PCa. These results indicate that some possible biomarker-candidate proteins are strongly influenced by the presence of inflammation, hence only a well-selected protein pattern should be considered for potential marker of PCa

Fast MacMillan's Imidazolidinone-Catalyzed Enantioselective Synthesis of Polyfunctionalized 4-Isoxazoline Scaffolds

The enantioselective 1,3-dipolar cycloaddition of nitrones and arylpropionaldehydes to generate highly functionalized scaffolds for application in drug discovery was herein investigated. The use of a second-generation MacMillan catalyst as hydrochloride salt consistently accelerated the reaction speed, allowing a decrease in the reaction time up to >100 times, still affording 4-isoxazolines with good to excellent enantiomeric ratios at room temperature. As a proof of concept, further functionalization of the isoxazoline core through Pd-catalyzed cross-coupling was performed, generating differently functionalized chemical architectures in high yield

Italian Guidelines in diagnosis and treatment of alopecia areata

Alopecia areata (AA) is an organ-specific autoimmune disorder that targets anagen phase hair follicles. The course is unpredictable and current available treatments have variable efficacy. Nowadays, there is relatively little evidence on treatment of AA from well-designed clinical trials. Moreover, none of the treatments or devices commonly used to treat AA are specifically approved by the Food and Drug Administration. The Italian Study Group for Cutaneous Annexial Disease of the Italian Society of dermatology proposes these Italian guidelines for diagnosis and treatment of Alopecia Areata deeming useful for the daily management of the disease. This article summarizes evidence-based treatment associated with expert-based recommendations

Economic consequences of investing in anti-HCV antiviral treatment from the Italian NHS perspective : a real-world-based analysis of PITER data

OBJECTIVE: We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy. METHODS: A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulative costs saved to recover the Italian NHS investment in DAA treatment. Three different PITER enrolment periods, which covered the full DAA access evolution in Italy, were considered. RESULTS: The disease stages of 2657 patients who consecutively underwent DAA therapy from January 2015 to December 2017 at 30 PITER clinical centres were standardized for 1000 patients. The investment in DAAs was considered to equal €25 million, €15 million, and €9 million in 2015, 2016, and 2017, respectively. For patients treated in 2015, the BPT was not achieved, because of the disease severity of the treated patients and high DAA prices. For 2016 and 2017, the estimated BPTs were 6.6 and 6.2 years, respectively. The total cost savings after 20 years were €50.13 and €55.50 million for 1000 patients treated in 2016 and 2017, respectively. CONCLUSIONS: This study may be a useful tool for public decision makers to understand how HCV clinical and epidemiological profiles influence the economic burden of HCV

Life cycle assessment of biodiesel production from micro-algae: a case study in Denmark

Le sperimentazioni riguardanti la produzione di biodiesel da alghe sono state condotte solo in laboratorio o in impianti pilota e il processo produttivo non è ancora stato sviluppato su scala industriale. L’obiettivo di questo lavoro di tesi è stato quello di valutare la potenziale sostenibilità ambientale ed energetica della produzione industriale di biodiesel da microalghe nella realtà danese ipotizzando la coltivazione in fotobioreattori. La tesi ha analizzato le diverse tecnologie attualmente in sperimentazione cercando di metterne in evidenza punti di forza e punti di debolezza. La metodologia applicata in questa tesi per valutare la sostenibilità ambientale ed energetica dei processi analizzati è LCA strumento che permette di effettuare la valutazione sull’intero ciclo di vita di un prodotto o di un processo. L’unità funzionale scelta è 1 MJ di biodiesel. I confini del sistema analizzato comprendono: coltivazione, raccolta, essicazione, estrazione dell’olio, transesterificazione, digestione anaerobica della biomassa residuale e uso del glicerolo ottenuto come sottoprodotto della transesterificazione. Diverse categorie d’impatto sono state analizzate. In questo caso studio, sono stati ipotizzati 24 diversi scenari differenziati in base alle modalità di coltivazione, di raccolta della biomassa, di estrazione dell’olio algale. 1. la produzione di biodiesel da microalghe coltivate in fotobioreattori non appare ancora conveniente né dal punto di vista energetico né da quello ambientale. 2. l’uso di CO2 di scarto e di acque reflue per la coltivazione, fra l’altro non ancora tecnicamente realizzabili, migliorerebbero le prestazioni energetiche ed ambientali del biodiesel da microalghe 3. la valorizzazione di prodotti secondari svolge un ruolo importante nel processo e nel suo sviluppo su larga scala Si conclude ricordando che il progetto di tesi è stato svolto in collaborazione con la Danish Technical University of Denmark (DTU) svolgendo presso tale università un periodo di tirocinio per tesi di sei mes